Evidence map›Paper›PMID 24873177›Full record

ArticleAccounts of chemical research2014

Heme utilization by pathogenic bacteria: not all pathways lead to biliverdin.

Angela Wilks, Masao Ikeda-Saito

Open access · bronzeAbstract read
In one paragraph

Article in Accounts of chemical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Biochemical and functional characterization ofFrontiers in microbiology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. HutW fromBiochemistry · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Angela WilksDepartment of Pharmaceutical Sciences, University of Maryland , Baltimore, Maryland 21201-1140, United States.
Masao Ikeda-Saito
Tohoku University · JPUniversity of Maryland, Baltimore · US

Funding

Heme utilization and homeostasis in Pseudomonas aeruginosaR01AI102883 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WILKS, ANGELA · 2013 to 2017
$2.0M
Heme Oxygenase: Structure, Function and PathogenesisR01AI055912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WILKS, ANGELA · 2004 to 2008
$1.3M
Heme Oxygenase: Structure, function and pathogenesisR56AI055912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WILKS, ANGELA · 2009 to 2010
$600k
NIAID NIH HHS AI102883NIAID NIH HHS AI55912NIAID NIH HHS R01 AI055912NIAID NIH HHS R01 AI102883NIAID NIH HHS R56 AI055912
6 · The paper itself

Abstract

The eukaryotic heme oxygenases (HOs) (E.C. 1.14.99.3) convert heme to biliverdin, iron, and carbon monoxide (CO) in three successive oxygenation steps. Pathogenic bacteria require iron for survival and infection. Extracellular heme uptake from the host plays a critical role in iron acquisition and virulence. In the past decade, several HOs required for the release of iron from extracellular heme have been identified in pathogenic bacteria, including Corynebacterium diphtheriae, Neisseriae meningitides, and Pseudomonas aeruginosa. The bacterial enzymes were shown to be structurally and mechanistically similar to those of the canonical eukaryotic HO enzymes. However, the recent discovery of the structurally and mechanistically distinct noncanonical heme oxygenases of Staphylococcus aureus and Mycobacterium tuberculosis has expanded the reaction manifold of heme degradation. The distinct ferredoxin-like structural fold and extreme heme ruffling are proposed to give rise to the alternate heme degradation products in the S. aureus and M. tuberculosis enzymes. In addition, several "heme-degrading factors" with no structural homology to either class of HOs have recently been reported. The identification of these "heme-degrading proteins" has largely been determined on the basis of in vitro heme degradation assays. Many of these proteins were reported to produce biliverdin, although no extensive characterization of the products was performed. Prior to the characterization of the canonical HO enzymes, the nonenzymatic degradation of heme and heme proteins in the presence of a reductant such as ascorbate or hydrazine, a reaction termed "coupled oxidation", served as a model for biological heme degradation. However, it was recognized that there were important mechanistic differences between the so-called coupled oxidation of heme proteins and enzymatic heme oxygenation. In the coupled oxidation reaction, the final product, verdoheme, can readily be converted to biliverdin under hydrolytic conditions. The differences between heme oxygenation by the canonical and noncanonical HOs and coupled oxidation will be discussed in the context of the stabilization of the reactive Fe(III)-OOH intermediate and regioselective heme hydroxylation. Thus, in the determination of heme oxygenase activity in vitro, it is important to ensure that the reaction proceeds through successive oxygenation steps. We further suggest that when bacterial heme degradation is being characterized, a systems biology approach combining genetics, mechanistic enzymology, and metabolite profiling should be undertaken.

Indexed as

BacteriaBiliverdineCarbon MonoxideCorynebacterium diphtheriaeEnzymesHemeHeme Oxygenase (Decyclizing)HydroxylationIronNeisseriaceaeOxidation-ReductionProtein Structure, TertiaryPseudomonas aeruginosaYin-YangBiliverdineCarbon MonoxideEnzymesHemeHeme Oxygenase (Decyclizing)Iron

Identifiers

PMID24873177
PMCPMC4139177
OpenAlexW2089763601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.